#### PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORIT' (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/JP2004/010270 13.07.2004 16.07.2003 International Patent Classification (IPC) or both national classification and IPC C08G14/00, G03F7/023 BEST AVAILABLE COPY Applicant TOKYO OHKA KOGYO CO., LTD. This opinion contains indications relating to the following items: 1. ☑ Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. III ☐ Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** ) If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. 3. **Authorized Officer** Name and mailing address of the ISA:

**)** 

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 Authorized Officer

Kiebooms, R

Telephone No. +49 89 2399-7816



**10/564510 IAP20 Rec'd FCT/FTO** 12 JAN 2006

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2004/010270

_						
_	Box	No. I Basis of the opinion				
1		With regard to the <b>language</b> , this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
2.	This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).					
	With regard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
	a. type of material:					
		a sequence listing				
		table(s) related to the sequence listing				
	b. fo	mat of material:				
		in written format				
		in computer readable form				
	c. tin	ne of filing/furnishing:				
		contained in the international application as filed.				
		filed together with the international application in computer readable form.				
		furnished subsequently to this Authority for the purposes of search.				
3		n addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.				
4.	Additional comments:					

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2004/010270

	Во	x No. II	Priority					
1.	$\boxtimes$	The following document has not been furnished:						
		$\boxtimes$	copy of the earlier	application	n whose pr	riority has been claimed (Rule 43bis.1 and 66.7(a)).		
			translation of the e	arlier appl	ication who	ose priority has been claimed (Rule 43bis.1 and 66.7(b)).		
						ider the validity of the priority claim. This opinion has tion that the relevant date is the claimed priority date.		
2.		has be	oinion has been est en found invalid (Ri ate indicated above	ules 43 <i>bis</i> .	1 and 64.1	rity had been claimed due to the fact that the priority claim  1). Thus for the purposes of this opinion, the international the relevant date.	I	
3.	3.  It has not been possible to consider the validity of the priority claim because a copy of the priority do was not available to the ISA at the time that the search was conducted (Rule 17.1). This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.							
4.	Ade	ditional d	observations, if nece	essary:				
			•	•				
_		11- 14	D		on Dudo 40	Ohio dialia was and to move the inventive atom or	_	
		x No. V Iustrial				3 <i>bis</i> .1(a)(i) with regard to novelty, inventive step or one supporting such statement		
1.	Sta	tement						
	No	velty (N)	•	Yes:	Claims			
				No:	Claims	1-5		
	Inv	entive s	tep (IS)	Yes:	Claims			
				No:	Claims	1-5		
	Ind	lustrial a	pplicability (IA)	Yes:	Claims	1-5		
				No:	Claims			
2.	. Cit	ations a	nd explanations					

see separate sheet

### IAP20 Rec'd FCT/PTO 12 JAN 2006

International application No.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

PCT/JP2004/010270

### Re Item V

(

()

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: EP-A-0 677 789 (FUJI PHOTO FILM CO LTD) 18 October 1995 (1995-10-18)

D2: EP-A-0 650 091 (SUMITOMO CHEMICAL CO) 26 April 1995 (1995-04-26)

D3: US-B-6 187 5001 (DOI KOUSUKE ET AL) 13 February 2001 (2001-02-13)

- 2.1 The expression "in which a portion of hydrogen atoms of all phenolic hydroxyl groups are substituted" is understood in the sense that the phenolic hydroxyls do not all have to be substituted. Since the words "portion" and the word "all" are inconsistent with one another, the applicant is advised to reformulate this expression in the claims where it is used so as to remove said inconsistency.
- 2.2 It is also not clear whether the compound labelled "dissolution promotor" is part of the novolak resin. If said dissolution promotors are being used to prepare the novolak resin, then they are also considered as being comprised in the positive photoresist composition of the application.
- 2.3 It appears that the photosensitizer of claim 3 can also be one of the compounds (b-1) or (b-11). If the photosensitizer of claim 3 should be a different compound, it should be mentioned explicitly in claim 3 that the photosensitizer should be different from compounds (b-1) and (b-11) of claim 1.
- 3. The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1-5 is not new in the sense of Article 33(2) PCT.
- 3.1 D1 discloses a photoresist composition comprising a novolak (D1, page 3, line 55 page 4, line 34; page 9, lines 33-57) with phenolic hydroxyl groups substituted with

()

()

1,2-naphthoquinonediazidosulfonyl groups (D1, page 11, line 11). D1 (Page 6-8; page 12, structures 13-15) further mentions the use of phenolic compounds corresponding with the structure of compound (b-11) of claim 1 of the present application.

Hence, the subject-matter of claims 1-5 is not new.

3.2 D2 discloses a photoresist composition comprising a novolak resin (D2, page 2, line 26 - page 3, line 21), novolac type phenolic hydroxyl groups substituted with 1,2-quinonediazide compounds (page 3, line 22 - page 5, line 9) and a compound (D2, examples 1-3, Table 4) corresponding with the structure of compound (b-1) of claim 1 of the present application.

Hence, the subject-matter of claims 1-5 is not new.

- 3.3 D3 discloses a composition comprising an alkali-soluble novolak (D3, column 6, line 5 column 8, line 2), a naphthoquinonediazide compound (D3, column 8, lines 5-50) and a sensitizer (D3, column 8, line 51 column 9, line 17; examples 1-9) Hence, the subject-matter of claims 1-5 is not new.
- 4. Since the Applicant has not provided information concerning the contribution to the existing state of the art of eventual remaining novel subject-matter, inventive step of such subject-matter cannot be accepted. The subject-matter of claims 1-5 is thus considered as an obvious alternative of the subject-matter disclosed in documents D1-D3.

The present application therefore cannot be considered as involving an inventive step (Article 33(3) PCT).